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Families of tumor-suppressor genes, such as those involved in homologous recom-
bination or mismatch repair, contain individual genes implicated in hereditary cancer 
syndromes. Collectively, such groupings establish that inactivating germline changes 
in genes within pathways related to genomic repair can promote carcinogenesis. The 
hypoxia pathway, whose activation is associated with aggressive and resistant sporadic 
tumors, is another pathway in which tumor-suppressor genes have been identified. von 
Hippel–Lindau disease, some of the hereditary paraganglioma–pheochromocytoma 
(PGL/PCC) syndromes, and the syndrome of hereditary leiomyomatosis and renal cell 
carcinoma are heritable conditions associated with genes involved or associated with 
the hypoxia pathway. This review links these heritable cancer syndromes to the hypoxia 
pathway while also comparing the relative aggression and treatment resistance of syn-
drome-associated tumors to similar, sporadic tumors. The reader will become aware of 
shared phenotypes (e.g., PGL/PCC, renal cell carcinoma) among these three hypox-
ia-pathway-associated heritable cancer syndromes as well as the known associations of 
tumor aggressiveness and treatment resistance within these pathways.
Keywords: von Hippel–Lindau disease, hereditary leiomyomatosis and renal cell cancer, SDHx hereditary 
paraganglioma–pheochromocytoma syndromes, hypoxia-inducible factor, pseudo-hypoxia
inTRODUCTiOn
Heritable cancer syndromes provide important clinical and research avenues. Clinically, diagnosing 
a heritable cancer syndrome allows a patient and his/her family to receive appropriate, targeted 
cancer screenings or preventive interventions. From a research standpoint, discovery and investiga-
tion of heritable cancer syndromes allows for better understanding of mechanisms of carcinogenesis 
and tumor behavior.
Families of tumor-suppressor genes consist of individual genes implicated in hereditary cancer 
syndromes that share common molecular pathways, such as the homologous recombination (e.g., 
BRCA1, BRCA2, PALB2) or mismatch repair (e.g., MLH1, MSH2, MSH6) pathways. Collectively, 
such groupings establish that inactivating germline changes in genes within pathways related 
to genomic repair can promote carcinogenesis. Insights related to these pathways led to the 
Abbreviations: FH, fumarate hydratase; HIF1, hypoxia-inducible factor 1; HLRCC, hereditary leiomyomatosis and renal cell 
cancer, PGL/PCC, paraganglioma–pheochromocytoma; RCC, renal cell carcinoma; SDH, succinate dehydrogenase; VEGF, 
vascular endothelial growth factor; VHL, von Hippel–Lindau.
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FiGURe 1 | Relationships between select heritable cancers and the hypoxia pathway. Inactivation of von Hippel–Lindau protein (pVHL), succinate 
dehydrogenase (SDH), or fumarate hydratase (FH) leads to increased expression of genes in the hypoxia pathway. (A) Tricarboxylic acid cycle and its relationship to 
regulation of hypoxia-inducible factor. (B) Inactivation of pVHL in von Hippel–Lindau disease causes upregulation of genes expressed in the hypoxia pathway 
through decreased degradation of HIF1-α. (C) Inactivation of SDH in the SDHx hereditary paraganglioma–pheochromocytoma syndromes causes increase in 
succinate, which inhibits prolyl hydroxylases that would assist in the degradation of HIF. (D) Inactivation of FH in HLRCC causes increase in fumarate, which inhibits 
prolyl hydroxylases that would assist in the degradation of HIF.
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development of pathway-related therapy (e.g., poly ADP ribose 
polymerase inhibitors) (1) and promising hypotheses regarding 
personalized, targeted therapy (e.g., PD-1 blockade in mismatch 
repair-deficient tumors) (2).
Families of tumor-suppressor genes have also been identified 
within or affecting pathways related to the tumor microenviron-
ment – in particular, the hypoxia pathway (Figure 1). Under nor-
mal cellular conditions, the transcription factor hypoxia-inducible 
factor 1 (HIF1) (3) regulates the cellular response to variations in 
oxygen tension. This transcription factor is a heterodimer formed 
by an alpha and a beta subunit. Degradation of the alpha subunit 
(HIF1-α) is regulated by oxygenation – when cellular oxygena-
tion is low HIF1-α degradation is decreased, allowing HIF1 to 
promote cellular survival and growth (3). In malignancies, this 
“hypoxia driver” phenotype utilizes the hypoxia pathway to pro-
duce an aggressive and/or resistant tumor (4). Pseudo-hypoxic 
states are ones that display similar hypoxia-pathway gene expres-
sion but under normoxic conditions. Pseudo-hypoxia may be 
achieved through inactivation of tumor-suppressor genes, such 
as the von Hippel–Lindau (VHL) tumor suppressor, E3 ubiquitin 
ligase gene (VHL); the genes associated with the succinate dehy-
drogenase (SDH) complex (the SDHx genes); and the fumarate 
hydratase (FH) gene.
The purpose of this review is to highlight the grouping of herit-
able cancer syndromes associated with genes (i.e., VHL, the SDHx 
genes, and FH) in or related to the hypoxia pathway. Since these 
syndromes involve germline mutations associated with activation 
of the hypoxia pathway, and activation of this pathway may lead 
to aggressive and resistant sporadic tumors, this review will also 
compare clinical aspects of carcinogenesis, tumor growth, local/
distant spread, and treatment resistance between syndrome-
associated tumors and similar sporadic tumors.
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vOn HiPPeL–LinDAU DiSeASe
von Hippel–Lindau disease is an autosomal-dominant hereditary 
cancer syndrome involving a germline mutation in VHL (5). In a 
VHL disease registry (6), tumors with a frequency of more than 
10% in VHL disease included retinal angiomas (41%), cerebellar 
hemangioblastomas (60%), spinal hemangioblastomas (15%), 
renal cell carcinomas (RCCs) (25%), and PCCs (15%). Pancreatic 
carcinomas, pituitary hemangioblastomas, and duodenal 
carcinoid tumors are described in 5% or less of patients. These 
frequencies are in line with other VHL disease reviews (7).
von Hippel–Lindau disease is diagnosed (6) in a patient who 
fulfills any one of the following four conditions: (1) two or more 
CNS hemangioblastomas; (2) one CNS hemangioblastoma and 
a disease-associated visceral tumor (i.e., RCC, PCC, pancreatic 
tumor or cysts, or broad ligament cystadenomas); (3) a family his-
tory of VHL disease and one of the following: (a) retinal angioma, 
(b) spinal or cerebellar hemangioblastoma, (c) PCC, (d) RCC, (e) 
or multiple renal and pancreatic cysts; or (4) a pathogenic VHL 
variant.
Clinically, VHL disease is associated with high penetrance and 
a shortened lifespan. VHL disease penetrance is an estimated 97% 
by 60 years of age (8). The three most common disease-related 
causes of death in VHL disease include cerebellar hemangioblas-
toma (48%), RCC (27%), and pancreatic carcinoma (7%) with a 
mean age of death of 40.9 years (6). In a review of a heritable can-
cer registry review, patients with VHL disease had a significantly 
shorter life expectancy than patients with four other heritable 
cancer syndromes  –  neurofibromatosis 1, neurofibromatosis 2, 
familial adenomatous polyposis, and Gorlin syndrome (9).
VHL is translated into von Hippel–Lindau tumor suppressor 
(pVHL), a hypoxia-associated protein. pVHL is a component of 
an intracellular multi-protein complex that also includes elongin 
C, elongin B, and cullin-2. This complex is an E3 ubiquitin protein 
ligase that, under conditions of adequate cellular oxygenation, 
targets HIF1-α for destruction (10) (Figure  1). VHL disease 
requires a mutation or in-frame deletion/insertion (11) of VHL 
that leads to loss of a functional protein. Loss of functional 
pVHL leads to upregulation of HIF that increases expression of 
various proteins (e.g., vascular endothelial growth factor (VEGF), 
platelet-derived growth factor, matrix metalloproteinases, and 
transforming growth factor-alpha) involved in cancer growth 
and development.
Despite VHL disease-associated tumors manifesting earlier 
in life than comparable sporadic ones (8), the VHL disease-
associated malignancies are less aggressive in their risk of local 
recurrence and distant spread. Reviews of registry data indicate 
that patients with VHL-associated RCC have a higher primary 
tumor size threshold for metastatic disease, a significantly higher 
overall survival (12), and an increased cancer-specific survival 
when compared to patients with similarly sized sporadic RCC 
(13). Other tumors associated with VHL disease also have less 
relative aggressiveness in regard to disease progression or recur-
rence. For example, when compared to similar sporadic tumors, 
VHL-associated endolymphatic sac tumors are less likely to 
invade surrounding structures (14), VHL-associated spinal 
hemangioblastomas are less likely to be clinically symptomatic 
(15), and resected VHL-associated pancreatic neuroendocrine 
tumors have a significantly lower rate of recurrence than similar 
sporadic tumors (16).
Malignancies associated with VHL disease seem to be as 
responsive, if not more so, than sporadic tumors to pharmacologic 
interventions. In a small, single institution retrospective review of 
patients with VHL disease treated with first-line sunitinib for either 
multifocal (29%) or metastatic (71%) RCC, there was a median 
progression-free survival of approximately 3.5 years with 9 of 14 
patients obtaining a partial response on therapy (17). For compari-
son, the phase 3 trial which led to sunitinib’s approval in metastatic 
RCC reported a median progression-free survival of 11 months 
and an objective response rate of 42% (18). Perhaps the potential 
higher response rate in VHL disease is not surprising, as a study 
of sporadic metastatic clear cell RCC indicated that patients with 
VHL inactivation have a higher, albeit not statistically significant 
different, response rate (41 versus 31%) to VEGF targeted therapy 
than did sporadic tumors with wild-type VHL (19).
In summary, VHL disease is highly penetrant and has a 
relatively early age of onset for its manifestations. However, VHL 
disease-associated tumors are less aggressive in regard to local 
invasion and to potential for metastatic spread as well as more 
responsive to therapy when compared to similar tumors.
SDHx HeReDiTARY PARAGAnGLiOMA–
PHeOCHROMOCYTOMA SYnDROMeS
The hereditary paraganglioma–pheochromocytoma (PGL/PCC) 
syndromes are a collection of autosomal-dominant hereditary 
cancer syndromes. Germline mutations associated with PGL/
PCC are clustered into two groups: those involved with the 
pseudo-hypoxic pathway and those involved in kinase signaling 
pathways. The former cluster includes mutations in genes related 
to SDH, known as the SDHx genes (20).
The SDHx hereditary PGL/PCC syndromes are relatively 
newly described entities that involve a mutation in SDHA, SDHB, 
SDHC, SDHD, or SDHAF2. In 2000, the first report was published 
of an association of one of the SDHx genes with hereditary PGL/
PCC syndromes (21). Since that time, in addition to PGL/PCC, 
the recognized tumor spectrum among patients with a mutation 
in one of the SDHx genes has been expanded to also include RCC, 
pituitary tumors, gastrointestinal stromal tumors, and pancreatic 
neuroendocrine tumors (22, 23). A meta-analysis of prevalence 
studies found the pooled risk for malignant PGL to be 13 and 
4% for SDHB and SDHD mutations, respectively (24). Penetrance 
may be affected by environmental oxygenation factors as patients 
with SDHD mutations who lived at lower (as opposed to higher) 
altitudes have less disease penetrance, have more findings of sin-
gle (as opposed to multiple) tumors, and do not typically develop 
PCCs (25).
The diagnosis of a SDHx hereditary PGL/PCC syndrome 
requires finding a germline mutation in one of the SDHx genes. 
In clinical practice, germline genetic testing may be considered 
in all patients with a PGL or PCC. However, some providers may 
consider factors related to the probability of detecting a mutation, 
such as tumor location, presence of multiple tumors, age of onset, 
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and pathological characteristics of the tumors in their decision to 
recommend germline molecular testing (26, 27).
The SDHx genes are involved in the structure and/or function 
of SDH. SDH catalyzes the conversion of succinate to fumarate 
in the tricarboxylic acid cycle by removing one hydrogen atom 
from each of the two methylene carbons of succinate and placing 
them in the respiratory chain (28) (Figure 1). The four subunits of 
SDH include two anchorage proteins (SDHD and SDHC) that are 
part of the mitochondrial membrane and two catalytic proteins 
(SDHA and SDHB) that transfer an electron to coenzyme Q. 
SDHAF2 encodes a protein needed for flavination of SDHA.
Succinate’s contribution to pseudo-hypoxia has been attrib-
uted to competitive inhibition of enzymes involved in HIF1-α 
degradation, changes in oxidative stress, changes in energy uti-
lization, and alterations in gene expression. The relative increase 
in the succinate-to-fumarate ratio is associated with succinate 
competitively inhibiting alpha-ketoglutarate in its binding to 
HIF1/2-α prolyl hydroxylases, thus preventing these enzymes 
from aiding in the degradation of HIF (Figure 1) (29) and leading 
to pseudo-hypoxia (30). PCCs with SDHB knockdown, like those 
in familial PGL/PCC, demonstrate HIF1-α stabilization despite 
normoxic conditions, consistent with pseudo-hypoxia (31). This 
has been recapitulated in tumor specimens where dysfunction of 
SDH due to mutations in SDHx genes leads to events consistent 
with pseudo-hypoxia, including mitochondrial dysfunction (32); 
increased expression of HIF1-α by immunohistochemistry (33); 
increased expression of miR-210, a key regulator of response to 
hypoxia (34); and increased VEGF expression (35). Other factors 
that may be involved in the malignant transformation, prolifera-
tion, and survival of SDHx-related tumors include an increase in 
reactive oxygen species, augmentation of the Warburg effect by 
HIF1-α, and utilization of glutamine as an energy source (29). 
Alterations in epigenetic regulation (36) and differential expres-
sions of stemness may also impact the malignant potential of 
SDHx-mutated PGL/PCC (37).
Paragangliomas associated with SDHB mutations are more 
aggressive and resistant to treatment than sporadic PGLs. 
Malignant PGLs more frequently have SDHB mutations than 
do sporadic tumors (38). In a retrospective study of 34 patients 
undergoing primary carotid body PGL resections, there was 
significantly worse disease-free survival among patients 
with a SDHB mutation than among patients without a SDHB 
mutation (39). In a cohort of patients with malignant PCC/
PGL, there was an association of decreased survival for those 
patients with a SDHB mutation compared to others within this 
cohort (40). Clinical trials (e.g., NCT02495103) are underway 
to explore targeted therapies for RCC associated with SDHx 
gene mutations.
The relatively recently discovered SDHx hereditary PGL/PCC 
syndromes highlight a method of carcinogenesis involving the 
hypoxia pathway. Pseudo-hypoxia in SDHx hereditary PGL/PCC 
syndrome tumors is achieved after substrate accumulation leads 
to competitive inhibition of an enzyme involved in degradation 
of HIF1-α. In contrast to VHL-associated tumors, tumors in 
hereditary PGL/PCC syndromes (especially those associated 
with SDHB germline mutations) behave more aggressively and 
are more resistant to therapy than their sporadic counterparts.
HeReDiTARY LeiOMYOMATOSiS AnD 
RenAL CeLL CAnCeR
Hereditary leiomyomatosis and renal cell cancer (HLRCC) 
is an autosomal-dominant hereditary cancer syndrome first 
associated with mutations in FH in 2002 (41). Clinically, patients 
with HLRCC may present with single or multiple cutaneous 
leiomyomata; uterine leiomyomata; and/or a RCC, which may 
be tubolo-papillary, collecting-duct, or papillary type 2 (42). 
The risk of RCC associated with HLRCC appears variable based 
on geography as kindreds in the United States of America and 
Finland, when compared to other countries, more often have 
multiple HLRCC-associated RCC cases (43).
Like the SDHx hereditary PGL/PCC syndromes, the diagnosis 
of HLRCC is made by molecular testing. Evaluation of FH should 
be considered if either there is (a) histologically confirmed mul-
tiple cutaneous leiomyomata or (b) at least two of the following: 
surgery required for symptomatic uterine leiomyomata before 
40 years of age, type 2 papillary RCC before 40 years of age, or 
a first-degree relative who meets one of the above criteria (44).
There is variable expression in HLRCC, with one study report-
ing 87% of patients with FH mutations having skin leiomyomata, 
96% of females having uterine leiomyomata (typically younger in 
age than those with sporadic tumors) (45), and 42% having RCC 
(46) – although a separate reviews put the risk of RCC between 
15 and 20% (47). A rare manifestation of germline FH mutations 
is PCC (48).
FH encodes FH, the tricarboxylic acid cycle enzyme that 
catalyzes the conversion of fumarate to malate (49) (Figure 1). 
The identification of FH as a tumor suppressor was the second 
description, following the identification of the SDHx genes in 
hereditary PGL/PCC syndromes, of a gene translated into an 
intermediary metabolism enzyme also being a tumor-suppressor 
gene (50). HLRCC is associated with FH germline changes that 
lead to a significant reduction in FH enzyme activity (51) and 
an accumulation of fumarate. Like succinate, fumarate acts as a 
competitive inhibitor of HIF prolyl hydroxylases, causing HIF 
upregulation (52).
Tumor specimens from patients with HLRCC demonstrate 
changes consistent with FH inactivation and pseudo-hypoxia. 
Leiomyomata associated with HLRCC have large increases in 
fumarate consistent with levels needed to impair HIF degrada-
tion (53). Leiomyomata associated with HLRCC, compared to 
sporadic leiomyomata, also demonstrate higher microvessel 
density and increased expression of anaerobic-associated 
or hypoxia responsive genes (54, 55). Other mechanisms of 
carcinogenesis may contribute to HLRCC tumor development 
as cellular models and cell lines of HLRCC-associated tumors 
demonstrate a dependence on glycolysis (56); alterations 
in expression of antioxidant-response element genes (57); 
changes in expression of genes involved in lipid metabolism, 
apoptosis, and energy production/glycolysis (58); and aberrant 
succination (59).
Hereditary leiomyomatosis and renal cell cancer-associated 
RCC is aggressive in its regional and distant spread but its relative 
resistance or susceptibility to therapy has yet to be demonstrated. 
Up to 47% of HLRCC patients with RCC present with nodal or 
5Henegan Jr. and Gomez Pseudo-Hypoxic Heritable Cancer Syndromes
Frontiers in Oncology | www.frontiersin.org March 2016 | Volume 6 | Article 68
distant metastases (60), as opposed to the 33% of patients with 
sporadic RCC (61). Some metastatic RCC lesions in HLRCC 
occur despite the primary tumor being <3  cm in size, leading 
to the recommendation that renal masses <3  cm cannot be 
observed in HLRCC – a departure from the recommendation for 
observation of small tumors in other RCC hereditary cancer syn-
dromes, including VHL disease (60). There is a lack of evidence 
to date regarding HLRCC-associated tumors’ responsiveness to 
therapy although clinical trials are underway to evaluate thera-
peutic options for patients with HLRCC-associated RCC (e.g., 
NCT01130519 and NCT02495103).
Hereditary leiomyomatosis and renal cell cancer shares many 
similarities with the SDHx hereditary PGL/PCC syndromes. 
Both are relatively newly discovered heritable cancer syndromes 
that involve a germline mutation in a tumor-suppressor gene that 
is translated into a tricarboxylic acid cycle enzyme. Both lead to 
competitive inhibition of an enzyme that in turn decreases the 
degradation of HIF1-α. Clinically, both are highly penetrant and 
can be associated with aggressive tumors.
DiSCUSSiOn
Like germline mutations in genes in the homologous recombina-
tion pathway and their association with hereditary breast and 
ovarian cancer; or germline mutations in mismatch repair genes 
and their association with colorectal cancer; germline mutations 
in genes associated with the hypoxia pathway (e.g., VHL, the SDHx 
genes, FH) appear to be associated with RCC and PGL/PCC. We 
suggest that future research should investigate the association of 
these germline mutations and these clinical phenotypes to assess, 
for instance, if perturbations within the hypoxia pathway drive a 
proportion of these tumor types.
A difference in aggressiveness and resistance to therapy was 
seen among these three heritable cancer syndromes associated 
with the hypoxia pathway (Table  1). VHL disease-associated 
tumors seem less aggressive and more responsive to therapy 
compared to similar sporadic tumors. However, tumors associ-
ated with the SDHx hereditary PGL/PCC syndromes as well 
as with HLRCC are more aggressive and there is ongoing 
research into potentially effective, personalized therapies for 
these syndromes. More research is needed to determine if the 
differential aggressiveness and resistance to therapy across 
these three syndromes is due to other effects associated with the 
germline mutations, such as alterations in energy metabolism or 
mitochondrial function.
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TABLe 1 | Aggressiveness and treatment resistance of tumors associated with heritable cancer syndromes that lead to pseudo-hypoxia compared to 
similar sporadic tumors.
 von Hippel–
Lindau Disease
Reference SDHx hereditary paraganglioma/
pheochromocytoma syndrome
Reference Hereditary leiomyomatosis 
and renal cell cancer
Reference 
Risk of local invasion Lower (14) No data NA No data NA
Risk of regional or 
distant spread
Lower (8) Higher (38) Higher (60)
Risk of recurrence Lower (8, 16) Higher (39) No data NA
Resistance to  
standard treatment
Less resistant (17) No data NA No data NA
Risk of death Lower (12, 13) Higher (40) No data NA
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